Bicara Therapeutics Inc. Common Stock (BCAX) - Stock Analysis
Last updated: Sep 20, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Minimal Debt ⢠High Cash Burn BCAX has ample liquidity and minimal debt, but no revenue, significant cash burn, and a premium 3.35x book valuation make it a high-risk, balance-sheet-dependent investment.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend persists ⢠Support bounce ⢠Resistance intact Support Level: $22.00 Resistance Level: $23.20â$23.70 BCAX remains bearish over the last month, with a modest bounce off $22.00 support needing a break above $23.20â$23.70 to signal a reversal.
Sentiment & News
Key News Insights: ⢠Employee inducements ⢠Routine hiring ⢠No catalysts Bicara granted inducement equity awards to two new hires, signaling routine recruitment activity with no new clinical, regulatory, or financial updates.
AI Summary
BCAX is a well-funded clinical-optionality betânot an operating businessâso investors should require meaningful efficacy or regulatory data before underwriting upside, as its $1.57B valuation already embeds pipeline success while ongoing cash burn and dilution magnify downside if trials disappoint.
Description
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeting monoclonal antibody with a domain that binds TGF-β. Founded in 2018 and based in Boston, the company is a subsidiary of Biocon Limited.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 19 | Mar 26 | BCAX | Bicara Therapeutics Inc. Common Stock | BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term. | Closed | +0.7% |